<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936009</url>
  </required_header>
  <id_info>
    <org_study_id>2000030576</org_study_id>
    <secondary_id>Proposal No. AR200174</secondary_id>
    <nct_id>NCT04936009</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation (TMS) Study for Adults With Autism Spectrum Disorder (ASD)</brief_title>
  <official_title>Noninvasive Brain Stimulation to Treat Core Social Deficits in Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized interventional study designed to evaluate the effects of repetitive&#xD;
      Transcranial Magnetic Stimulation (rTMS) on neural and behavioral facets of social cognition&#xD;
      in adults with autism spectrum disorder (ASD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine whether rTMS increases the brain response&#xD;
      to faces in a population of adults with ASD. This study will assess critical aspects of&#xD;
      social cognition using the electroencephalogram (EEG), event-related potentials (ERPS), and&#xD;
      eye-tracking (ET) prior to and following a single rTMS session (or Sham) to provide&#xD;
      preliminary insight into the potential of rTMS as a tool to modify social brain function in&#xD;
      this population.&#xD;
&#xD;
      Participant visits will include a baseline assessment of neuropsychological, cognitive and&#xD;
      behavioral function, and a pre and post TMS session with EEG (electroencephalogram) and&#xD;
      eye-tracking to measure neural and visual attentional social response. Two study visits will&#xD;
      be scheduled for each participant lasting approximately 4-5hrs total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will receive both active and sham TMS in a randomized crossover assignment involving two study sessions.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will not know whether they are receiving active or sham TMS until both sessions have been completed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>right hemisphere N170 latency</measure>
    <time_frame>Measures will be recorded during the EEG/ET sessions of participant visits for an expected 1-2 hours</time_frame>
    <description>EEG brain response to faces as measured by the N170 component in milliseconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>proportion of visual attention to the eye region of the face</measure>
    <time_frame>Measures will be recorded during the EEG/ET sessions of participant visits for an expected 1-2 hours</time_frame>
    <description>visual attention to the eye region of the face as measured by eye tracking in seconds</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Transcranial Magnetic Stimulation - real</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive active TMS during their study visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcranial Magnetic Stimulation - sham</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive sham stimulation during their study visit simulating TMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation (TMS)</intervention_name>
    <description>Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions</description>
    <arm_group_label>Transcranial Magnetic Stimulation - real</arm_group_label>
    <arm_group_label>Transcranial Magnetic Stimulation - sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals between the ages of 18 and 30 years old with typical development or with a&#xD;
             diagnosis of autism spectrum disorder.&#xD;
&#xD;
          -  Individuals able to participate in an EEG and eye-tracking experiment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants reporting significant head trauma or serious brain illness.&#xD;
&#xD;
          -  Participants with major psychiatric illness that would preclude completion of study&#xD;
             measures.&#xD;
&#xD;
          -  Participants with a history of serious medical illness, stroke, seizures, epileptiform&#xD;
             EEG abnormalities, or family history of seizures.&#xD;
&#xD;
          -  Participants taking prescription medications that may affect cognitive processes under&#xD;
             study.&#xD;
&#xD;
          -  Participants who have taken alcohol or recreational drugs within the preceding 24&#xD;
             hours.&#xD;
&#xD;
          -  Females of known/suspected pregnancy or who test positive on a pregnancy test.&#xD;
&#xD;
          -  Participants with a history of metalworking or injury by shrapnel or metallic objects&#xD;
             are also excluded.&#xD;
&#xD;
          -  Participants with a history of prior TMS therapy or use of an investigational drug&#xD;
             within 12 weeks of visit.&#xD;
&#xD;
          -  Participants with an IQ below 80.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McPartland, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Wright, BS</last_name>
    <phone>203-785-3488</phone>
    <email>n.wright@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Naples, PhD</last_name>
    <phone>203-785-2583</phone>
    <email>adam.naples@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University Child Study Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicole Wright</last_name>
      <phone>860-785-3488</phone>
      <email>n.wright@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Naples, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James McPartland, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14. Review.</citation>
    <PMID>19833552</PMID>
  </reference>
  <reference>
    <citation>Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron. 2005 Jan 20;45(2):201-6.</citation>
    <PMID>15664172</PMID>
  </reference>
  <reference>
    <citation>Allison T, Puce A, McCarthy G. Social perception from visual cues: role of the STS region. Trends Cogn Sci. 2000 Jul;4(7):267-278.</citation>
    <PMID>10859571</PMID>
  </reference>
  <reference>
    <citation>McPartland J, Dawson G, Webb SJ, Panagiotides H, Carver LJ. Event-related brain potentials reveal anomalies in temporal processing of faces in autism spectrum disorder. J Child Psychol Psychiatry. 2004 Oct;45(7):1235-45.</citation>
    <PMID>15335344</PMID>
  </reference>
  <reference>
    <citation>Dawson G, Toth K, Abbott R, Osterling J, Munson J, Estes A, Liaw J. Early social attention impairments in autism: social orienting, joint attention, and attention to distress. Dev Psychol. 2004 Mar;40(2):271-83.</citation>
    <PMID>14979766</PMID>
  </reference>
  <reference>
    <citation>Oberman LM, Rotenberg A, Pascual-Leone A. Use of transcranial magnetic stimulation in autism spectrum disorders. J Autism Dev Disord. 2015 Feb;45(2):524-36. doi: 10.1007/s10803-013-1960-2. Review.</citation>
    <PMID>24127165</PMID>
  </reference>
  <reference>
    <citation>Abujadi C, Croarkin PE, Bellini BB, Brentani H, Marcolin MA. Intermittent theta-burst transcranial magnetic stimulation for autism spectrum disorder: an open-label pilot study. Braz J Psychiatry. 2018 Jul-Sep;40(3):309-311. doi: 10.1590/1516-4446-2017-2279. Epub 2017 Dec 11.</citation>
    <PMID>29236921</PMID>
  </reference>
  <reference>
    <citation>Ni HC, Hung J, Wu CT, Wu YY, Chang CJ, Chen RS, Huang YZ. The Impact of Single Session Intermittent Theta-Burst Stimulation over the Dorsolateral Prefrontal Cortex and Posterior Superior Temporal Sulcus on Adults with Autism Spectrum Disorder. Front Neurosci. 2017 May 9;11:255. doi: 10.3389/fnins.2017.00255. eCollection 2017.</citation>
    <PMID>28536500</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 13, 2021</study_first_submitted>
  <study_first_submitted_qc>June 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

